Positive Clinical Outcomes Bolster UroGen Pharma’s (URGN) Prospects
UroGen Pharma Ltd. (NASDAQ: URGN) stock saw a notable uptrend of 37.58% to close the previous session at $17.50 after disclosing positive clinical trial findings. UroGen shared that based on Kaplan-Meier projections from its Phase 3 ENVISION study, 82.3% of patients sustained a 12-month duration of response (DOR). In this experiment, patients who experienced a […]